RxSight Inc.
Last updated September 27, 2026
Organization details
- Legal name
- RxSight Inc.
- Former names
- Calhoun Vision Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 3851 — Ophthalmic Goods
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Aliso Viejo
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- RXST
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001111485
- EIN
- 94-3268801
Board of directors
-
Aziz Mottiwala · Director · President and CEOSince 2026
-
Bakker Juliet Tammenoms · DirectorSince 2023
-
Jesse Anderson Corley · DirectorSince 2023
-
Julie Andrews · DirectorSince 2023
-
Raymond W. Cohen · DirectorSince 2025
-
Robert J. Palmisano · DirectorSince 2023
-
Robert Keith Warner · DirectorSince 2023
-
Ronald M. Kurtz M.D. · Director · President & CEOSince 2023
-
Shweta Maniar · DirectorSince 2023
-
Tamara Fountain · DirectorSince 2023
-
William J. Link Ph.D. · DirectorSince 2023
Chief executives
Aziz Mottiwala
· President and CEO
Since July 2026
Ronald M. Kurtz M.D.
· President & CEO
Until July 2026
· Former
Director election results
Annual meeting of June 16, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
100.0%
-
100.0%
-
100.0%
Board connections
6 of this board's directors also sit on 8 other boards.
- via Robert J. Palmisano
- via Bakker Juliet Tammenoms
- via Raymond W. Cohen
- via Raymond W. Cohen
- via William J. Link Ph.D.
- via Shweta Maniar
- via Tamara Fountain
- via William J. Link Ph.D.
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $117,951
- 4 sales by 4 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 15, 2026 | Weinberg Eric Officer (See remarks) | Option exercise | +35,168 | $4.34 | $152,629 |
| Sep 2, 2026 | Goldshleger Ilya Officer (Chief Operating Officer) | Open-market sale | −2,041 | $6.96 | $14,205 |
| Sep 2, 2026 | Ronald M. Kurtz M.D. Officer (Chief Medical Officer) | Open-market sale | −5,100 | $6.96 | $35,496 |
| Sep 2, 2026 | Weinberg Eric Officer (See remarks) | Open-market sale | −2,041 | $6.96 | $14,205 |
| Sep 2, 2026 | Wilterding Mark Officer (Chief Financial Officer) | Open-market sale | −7,765 | $6.96 | $54,044 |
| Aug 31, 2026 | Goldshleger Ilya Officer (Chief Operating Officer) | Option exercise | +5,370 | — | — |
| Aug 31, 2026 | Ronald M. Kurtz M.D. Officer (Chief Medical Officer) | Option exercise | +13,425 | — | — |
| Aug 31, 2026 | Weinberg Eric Officer (See remarks) | Option exercise | +5,370 | — | — |
| Aug 31, 2026 | Wilterding Mark Officer (Chief Financial Officer) | Option exercise | +20,441 | — | — |
| Jun 17, 2026 | Robert Keith Warner Director | Grant or award | +37,037 | — | — |
| Jun 17, 2026 | Robert J. Palmisano Director | Grant or award | +37,037 | — | — |
| Jun 17, 2026 | Shweta Maniar Director | Grant or award | +37,037 | — | — |
| Jun 17, 2026 | Tamara Fountain Director | Grant or award | +37,037 | — | — |
| Jun 17, 2026 | William J. Link Ph.D. Director | Grant or award | +37,037 | — | — |
| Jun 17, 2026 | Jesse Anderson Corley Director | Grant or award | +37,037 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.